Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.

ABSTRACT:

Background

There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking.

Method

This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy.

Results

A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was high

SUBMITTER: Incorvaia L 

PROVIDER: S-EPMC11150359 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature